

# Nicholas P Van Der Meulen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/515568/publications.pdf>

Version: 2024-02-01

69  
papers

2,178  
citations

186265

28  
h-index

233421

45  
g-index

71  
all docs

71  
docs citations

71  
times ranked

1408  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of terbium-161 with somatostatin receptor antagonistsâ€™ a potential paradigm shift for the treatment of neuroendocrine neoplasms. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1113-1126.	6.4	32
2	The Metamorphosis of Radionuclide Production and Development at Paul Scherrer Institute. <i>Chimia</i> , 2022, 74, 968.	0.6	5
3	Targeted Radiotherapeutics from 'Bench-to-Bedside'. <i>Chimia</i> , 2022, 74, 939.	0.6	5
4	Non-conventional radionuclides: The pursuit for perfection. , 2022, , 133-142.		1
5	Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161. <i>EJNMMI Physics</i> , 2022, 9, 19.	2.7	5
6	Cross section measurement of terbium radioisotopes for an optimized <sup>155</sup> Tb production with an 18 MeV medical PET cyclotron. <i>Applied Radiation and Isotopes</i> , 2022, 184, 110175.	1.5	18
7	Chelation of Theranostic Copper Radioisotopes with S-Rich Macrocycles: From Radiolabelling of Copper-64 to In Vivo Investigation. <i>Molecules</i> , 2022, 27, 4158.	3.8	5
8	In Vivo Imaging of Local Inflammation: Monitoring LPS-Induced CD80/CD86 Upregulation by PET. <i>Molecular Imaging and Biology</i> , 2021, 23, 196-207.	2.6	12
9	First-in-Humans Application of <sup>161</sup> Tb: A Feasibility Study Using <sup>161</sup> Tb-DOTATOC. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1391-1397.	5.0	42
10	Dosimetric Analysis of the Short-Ranged Particle Emitter <sup>161</sup> Tb for Radionuclide Therapy of Metastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 2011.	3.7	19
11	Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations. <i>Frontiers in Medicine</i> , 2021, 8, 643175.	2.6	11
12	Simultaneous Visualization of <sup>161</sup> Tb- and <sup>177</sup> Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging. <i>Pharmaceutics</i> , 2021, 13, 536.	4.5	17
13	CERN-MEDICIS: A Review Since Commissioning in 2017. <i>Frontiers in Medicine</i> , 2021, 8, 693682.	2.6	22
14	Determination of the gamma and X-ray emission intensities of terbium-161. <i>Applied Radiation and Isotopes</i> , 2021, 174, 109770.	1.5	3
15	Determination of the gamma and X-ray emission intensities of erbium-169. <i>Applied Radiation and Isotopes</i> , 2021, 176, 109823.	1.5	4
16	Ytterbium-175 half-life determination. <i>Applied Radiation and Isotopes</i> , 2021, 176, 109893.	1.5	3
17	Fifty Shades of Scandium: Comparative Study of PET Capabilities Using Sc-43 and Sc-44 with Respect to Conventional Clinical Radionuclides. <i>Diagnostics</i> , 2021, 11, 1826.	2.6	10
18	Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 37.	3.9	25

#	ARTICLE	IF	CITATIONS
19	Terbium radionuclides for theranostics. , 2021, , .		0
20	New Radionuclides and Technological Advances in SPECT and PET Scanners. <i>Cancers</i> , 2021, 13, 6183.	3.7	16
21	Developments toward the Implementation of <sup>44</sup> Sc Production at a Medical Cyclotron. <i>Molecules</i> , 2020, 25, 4706.	3.8	38
22	First Phantom-Based Quantitative Assessment of Scandium-44 Using a Commercial PET Device. <i>Frontiers in Physics</i> , 2020, 8, .	2.1	5
23	Expanding the Scope of Pyclyen-Picolinate Lanthanide Chelates to Potential Theranostic Applications. <i>Inorganic Chemistry</i> , 2020, 59, 11736-11748.	4.0	14
24	Activity standardisation of <sup>161</sup> Tb. <i>Applied Radiation and Isotopes</i> , 2020, 166, 109411.	1.5	5
25	Determination of <sup>161</sup> Tb half-life by three measurement methods. <i>Applied Radiation and Isotopes</i> , 2020, 159, 109085.	1.5	25
26	A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with <sup>68</sup> Ga, <sup>44</sup> Sc, <sup>177</sup> Lu and <sup>161</sup> Tb. <i>Molecules</i> , 2020, 25, 966.	3.8	36
27	<sup>165</sup> Er: A new candidate for Auger electron therapy and its possible cyclotron production from natural holmium targets. <i>Applied Radiation and Isotopes</i> , 2020, 159, 109079.	1.5	14
28	Preclinical investigations and first-in-human application of <sup>152</sup> Tb-PSMA-617 for PET/CT imaging of prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 68.	2.5	39
29	From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 422-437.	4.6	30
30	Production and characterization of no-carrier-added <sup>161</sup> Tb as an alternative to the clinically-applied <sup>177</sup> Lu for radionuclide therapy. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 12.	3.9	56
31	Internal radiation dosimetry of a <sup>152</sup> Tb-labeled antibody in tumor-bearing mice. <i>EJNMMI Research</i> , 2019, 9, 53.	2.5	17
32	Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute. <i>Pharmaceutics</i> , 2019, 11, 450.	4.5	4
33	Therapeutic Potential of <sup>47</sup> Sc in Comparison to <sup>177</sup> Lu and <sup>90</sup> Y: Preclinical Investigations. <i>Pharmaceutics</i> , 2019, 11, 424.	4.5	24
34	Radiometals for imaging and theranostics, current production, and future perspectives. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 615-634.	1.0	49
35	Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1919-1930.	6.4	109
36	Implementation of a new separation method to produce qualitatively improved <sup>64</sup> Cu. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 460-470.	1.0	14

#	ARTICLE	IF	CITATIONS
37	Alpha-PET for Prostate Cancer: Preclinical investigation using <sup>149</sup> Tb-PSMA-617. Scientific Reports, 2019, 9, 17800.	3.3	49
38	Measurement of the <sup>43</sup> Sc production cross-section with a deuteron beam. Applied Radiation and Isotopes, 2019, 145, 205-208.	1.5	9
39	Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. British Journal of Radiology, 2018, 91, 20180074.	2.2	120
40	In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs. Molecular Pharmaceutics, 2018, 15, 4995-5004.	4.6	9
41	Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for <sup>64</sup> Cu-Based PET Imaging. Molecular Pharmaceutics, 2018, 15, 5556-5564.	4.6	28
42	High Efficiency Cyclotron Trap Assisted Positron Moderator. Instruments, 2018, 2, 10.	1.8	3
43	Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 5.	3.9	72
44	<sup>44</sup> Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 8.	3.9	53
45	<sup>44</sup> Sc-PSMA-617 for radiotheragnostics in tandem with <sup>177</sup> Lu-PSMA-617: preclinical investigations in comparison with <sup>68</sup> Ga-PSMA-11 and <sup>68</sup> Ga-PSMA-617. EJNMMI Research, 2017, 7, 9.	2.5	140
46	First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced <sup>44</sup> Sc-DOTATOC: A Proof-of-Concept Study. Cancer Biotherapy and Radiopharmaceutics, 2017, 32, 124-132.	1.0	52
47	Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with <sup>152</sup> Tb-DOTATOC. Dalton Transactions, 2017, 46, 14638-14646.	3.3	61
48	Therapeutic Radiometals Beyond <sup>177</sup> Lu and <sup>90</sup> Y: Production and Application of Promising <sup>125</sup> I-Particle, <sup>125</sup> Te-Particle, and Auger Electron Emitters. Journal of Nuclear Medicine, 2017, 58, 91S-96S.	5.0	58
49	Concurrent spectrometry of annihilation radiation and characteristic gamma-rays for activity assessment of selected positron emitters. Applied Radiation and Isotopes, 2017, 129, 76-86.	1.5	3
50	Measurement of <sup>43</sup> Sc and <sup>44</sup> Sc production cross-section with an 18 MeV medical PET cyclotron. Applied Radiation and Isotopes, 2017, 129, 96-102.	1.5	61
51	<sup>47</sup> Sc as useful <sup>125</sup> I-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 5.	3.9	60
52	Evaluation of the first <sup>44</sup> Sc-labeled Affibody molecule for imaging of HER2-expressing tumors. Nuclear Medicine and Biology, 2017, 45, 15-21.	0.6	26
53	Production and separation of <sup>43</sup> Sc for radiopharmaceutical purposes. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 14.	3.9	45
54	<sup>64</sup> Cu- and <sup>68</sup> Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate. Molecular Pharmaceutics, 2016, 13, 1979-1987.	4.6	41

#	ARTICLE	IF	CITATIONS
55	Production of $^{28}\text{Mg}$ by bombardment of $\text{natCl}$ with 200 MeV protons: Proof-of-concept study for a stacked $\text{LiCl}$ target. <i>Applied Radiation and Isotopes</i> , 2016, 115, 125-132.	1.5	1
56	Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of $^{161}\text{Tb}$ -folate and $^{177}\text{Lu}$ -folate. <i>EJNMMI Research</i> , 2016, 6, 13.	2.5	43
57	Preclinical in vivo application of $^{152}\text{Tb}$ -DOTANOC: a radiolanthanide for PET imaging. <i>EJNMMI Research</i> , 2016, 6, 35.	2.5	40
58	Imaging quality of $^{44}\text{Sc}$ in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET. <i>Applied Radiation and Isotopes</i> , 2016, 110, 129-133.	1.5	43
59	Cyclotron production of $^{44}\text{Sc}$ : From bench to bedside. <i>Nuclear Medicine and Biology</i> , 2015, 42, 745-751.	0.6	91
60	Future prospects for SPECT imaging using the radiolanthanide terbium-155 $\beta^-$ production and preclinical evaluation in tumor-bearing mice. <i>Nuclear Medicine and Biology</i> , 2014, 41, e58-e65.	0.6	60
61	Promising Prospects for $^{44}\text{Sc}$ -/ $^{47}\text{Sc}$ -Based Theragnostics: Application of $^{47}\text{Sc}$ for Radionuclide Tumor Therapy in Mice. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1658-1664.	5.0	163
62	Positron emission particle tracking measurements with 50 micron tracers. <i>Chemical Engineering Science</i> , 2012, 75, 235-242.	3.8	25
63	Studies of the effect of tracer activity on time-averaged positron emission particle tracking measurements on tumbling mills at PEPT Cape Town. <i>Minerals Engineering</i> , 2011, 24, 261-266.	4.3	35
64	The use of selective volatilization in the separation of $^{68}\text{Ge}$ from irradiated Ga targets. <i>Applied Radiation and Isotopes</i> , 2011, 69, 727-731.	1.5	9
65	The isolation of $^{133}\text{Ba}$ produced by proton-induced reactions on Cs using cation exchange chromatography. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2010, 285, 491-498.	1.5	4
66	The production of $^{88}\text{Y}$ in the proton bombardment of $\text{natSr}$ : New excitation and separation studies. <i>Applied Radiation and Isotopes</i> , 2009, 67, 1320-1323.	1.5	17
67	Radiochemical separation of $^{88}\text{Y}$ from a $\text{SrCl}_2$ target using chelating resin Chelex 100. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2006, 270, 641-643.	1.5	14
68	Production of $^{111}\text{In}$ from an $\text{In}/\text{In}_2\text{O}_3$ target. <i>Radiochimica Acta</i> , 2005, 93, 575-577.	1.2	1
69	Separation of $^{103}\text{Pd}$ from Rh and Ag by the macroporous AG MP-1 anion exchange resin in Ag targets. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2003, 256, 31-35.	1.5	5